The ANTARCTIC trial does not provide sufficient evidence to refute the utility of platelet function monitoring in patients with high risk of coronary artery disease. Future trials on personalized antiplatelet therapy should try to address the limitations of previous studies.
This is a preview of subscription content, log in via an institution to check access.
References
Gurbel, P. A., Jeong, Y. H., Navarese, E. P. & Tantry, U. S. Platelet-mediated thrombosis: from bench to bedside. Circ. Res. 118, 1380–1391 (2016).
Cayla, G. et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomized controlled superiority trial. Lancet http://dx.doi.org/10.1016/S0140-6736(16)31323-X (2016).
Gurbel, P. A. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46, 1820–1826 (2005).
Reny, J. L. et al. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. Thromb. Haemost. 115, 844–855 (2016).
Bonello, L. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404–1411 (2008).
Campo, G. et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56, 1447–1455 (2010).
Price, M. J. et al. Standard- versus high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097–1105 (2011).
Collet, J. P. et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367, 2100–2109 (2012).
Erlinge, D. et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J. Am. Coll. Cardiol. 62, 577–583 (2013).
Gurbel, P. A. et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308, 1785–1794 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.A.G. has received consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo/Lilly, Haemonetics, Janssen Pharmaceuticals, Merck, and New Haven Pharmaceuticals; grants from Coramed Technologies, Duke Clinical Research Institute, Haemonetics, Harvard Clinical Research Institute, MedImmune, Merck, National Institutes of Health, New Haven Pharmaceuticals, and Sinnowa. He also owns a patent for platelet function testing, and stock options in Merck. U.S.T. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Gurbel, P., Tantry, U. What have we learned from the ANTARCTIC trial?. Nat Rev Cardiol 13, 639–640 (2016). https://doi.org/10.1038/nrcardio.2016.167
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2016.167
- Springer Nature Limited